Skip Navigation


ToxSci Advance Access originally published online on December 22, 2005
Toxicological Sciences 2006 90(2):440-450; doi:10.1093/toxsci/kfj081
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
90/2/440    most recent
kfj081v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stoll, R. E.
Right arrow Articles by Mennear, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stoll, R. E.
Right arrow Articles by Mennear, J. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Phenolphthalein and Bisacodyl: Assessment of Genotoxic and Carcinogenic Responses in Heterozygous p53 (+/–) Mice and Syrian Hamster Embryo (SHE) Assay

R. E. Stoll*,1, K. T. Blanchard{dagger}, J. H. Stoltz{dagger}, J. B. Majeska{dagger}, S. Furst{ddagger}, P. D. Lilly§ and J. H. Mennear

* Stoll & Associates, LLC, Storrs Mansfield, Connecticut 06268; {dagger} Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877; {ddagger} Pfizer, Inc., Ann Arbor, Michigan 48108; § Chrysalis, Inc., Richmond, Virginia 23113; and Campbell University, Buies Creek, North Carolina 27506

Received September 9, 2005; accepted December 20, 2005

Phenolphthalein (800 and 2400 mg/kg/day by gavage and 2400 mg/kg/day by diet) and bisacodyl (800–500, 4000–2000, and 8000 mg/kg/day by gavage) were administered to 15 male and 15 female and 20 male and 20 female p53+/– mice respectively for 26 weeks to investigate the potential carcinogenicity of each compound. Toxicokinetic analyses confirmed systemic exposure. p-Cresidine was administered by gavage (400 mg/kg/day) and served as the positive control agent in each study. Dietary phenolphthalein reduced survival in both sexes and early deaths were attributed to thymic lymphoma. No bisacodyl-related neoplasms were observed. Regardless of route of administration to p53+/– mice, phenolphthalein but not bisacodyl was unequivocally genotoxic, causing increased micronuclei in polychromatic erythrocytes. In the Syrian hamster embryo (SHE) cell transformation assay, phenolphthalein caused increases in morphologically transformed colonies, thereby corroborating NTP's earlier reports, showing phenolophthalein has potential carcinogenic activity. Bisacodyl was negative in the SHE assay. Results of these experiments confirm an earlier demonstration that dietary phenolphthalein causes thymic lymphoma in p53+/– mice and show that (1) phenolphthalein causes qualitatively identical results in this transgenic model regardless of route of oral administration, (2) phenolphthalein shows evidence of micronucleus induction in p53+/– mice for up to 26 weeks, (3) phenolphthalein induced transformations in the in vitro SHE assay, and (4) bisacodyl in p53+/– mice induces neither drug-related neoplasm, nor micronuclei in polychromatic erythrocytes, and did not induce transformations in the in vitro SHE assay.

Key Words: phenolphthalein; bisacodyl; carcinogenicity; p53 transgenic; laxatives; SHE assay.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.